DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
- Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data, into one continuous learning engine
- Announces collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), as a client
London, UK – 4 June 2026 – DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, today announced the launch of Dalton, its drug discovery platform. DaltonTx also announced that it has entered into a collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), to use the Dalton platform to further strengthen its AI-enabled drug discovery capabilities and accelerate medicinal chemistry decision-making while safeguarding customer data.
